| All (n = 165) | MMAS-8 | p value | ||
---|---|---|---|---|---|
Low (n = 20) | Medium (n = 99) | High (n = 46) | |||
Age, median (IQR) | 64 (54–72) | 58 (44–62) | 65 (53–73) | 65.5 (59–74) | 0.01 |
Female, n (%) | 142 (86.1) | 18 (90.0) | 84 (84.6) | 38 (82.6) | 0.74 |
MTX dose (mg/week), median (IQR) | 8 (6–12) | 10 (8–12) | 8 (6–10) | 10 (8–12) | 0.17 |
MTX dosing frequency (times/week), median (IQR) | 3 (2–3) | 3 (2–3) | 2 (2–3) | 2 (2–3) | 0.54 |
Duration of MTX treatment (month), median (IQR) | 36 (17–75) | 32 (16–79) | 35 (18–80) | 41 (13–74) | 0.15 |
Disease duration (month), median (IQR) | 53.5 (22.5–123.5) | 35 (22–120) | 47 (22–111) | 60.5 (24–158) | 0.95 |
Concomitant medication | |||||
NSAIDS, n (%) | 59 (35.8) | 5 (25.0) | 36 (36.4) | 8 (39.1) | 0.53 |
Corticosteroid, n (%) | 27 (16.4) | 2 (10.0) | 17 (17.2) | 8 (17.4) | 0.71 |
Biologics, n (%) | 48 (29.1) | 7 (35.0) | 28 (28.3) | 13 (28.3) | 0.83 |
DAS28-ESR, median (IQR) | 2.30 (1.68–3.00) | 2.01 (1.37–2.23) | 2.32 (1.68–3.02) | 2.40 (2.01–3.15) | 0.08 |
mHAQ, median (IQR) | 0 (0–0.13) | 0 (0–0.25) | 0 (0–0) | 0.13 (0–0.38) | 0.02 |
BMQ necessity-concern differential, median (IQR) | 1 (0–3) | 2 (0–3) | 1 (0–3) | 2 (0–3) | 0.81 |
CES-D (total score ≥ 16), n (%) | 37 (26.4) | 8 (47.1) | 21 (8.3) | 8 (20.0) | 0.10 |
BPI (average NRS pain score), median (IQR) | 2 (1–3) | 1 (1–4) | 1 (1–3) | 1 (3–4) | 0.13 |
SDS, median (IQR) | 6 (4–7) | 4 (3–6) | 6 (4–6) | 6.5 (5–8) | 0.00 |
SF-8 (PCS), median (IQR) | 48.1 (42.4–52.1) | 47.4 (45.8–52.1) | 49.8 (43.5–52.1) | 45.6 (40.2–50.2) | 0.04 |
SF-8 (MCS), median (IQR) | 50.2 (45.6–54.1) | 47.7 (43.0–53.2) | 50.3 (46.3–53.9) | 50.0 (46.1–55.0) | 0.36 |
Marital status (married), n (%) | 95 (57.9) | 11 (55.0) | 61 (62.2) | 23 (50.0) | 0.37 |
Educational level (greater than or equal to college level), n (%) | 36 (21.8) | 5 (25.0) | 17 (17.2) | 14 (30.4) | 0.19 |
Employment status (full-time), n (%) | 38 (23.0) | 12 (60.0) | 22 (22.2) | 4 (8.7) | 0.00 |
Living status (living alone), n (%) | 43 (26.4) | 7 (35.0) | 24 (24.5) | 12 (26.7) | 0.62 |